Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor (CAR) T cell therapy, even after prior…

Continue Reading

News Source: medicalxpress.com